Anocca AB (Anocca), a clinical-stage T-cell immunotherapy company, raised SEK ~440 million (USD ~46 million) in financing. Mellby Gård led the financing with strong support from AMF, Ramsbury, and existing shareholders, alongside new investors. The additional capital will be used to drive the continued progress of VIDAR-1, Anocca’s gene-edited TCR-T cell therapies targeting mutant KRAS in pancreatic cancer, through early-stage clinical development, as well as progress Anocca’s preclinical pip...